Arcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.
Arcus Biosciences has raised $250.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.
Arcus Biosciences's investors include Wellington Management, Hillhouse Investment, Foresite Capital, Gilead Sciences, Novartis.
Arcus Biosciences is headquartered in Hayward, United States.
Arcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.
Arcus Biosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Arcus Biosciences — Funding & Investors." VCBacked, October 30, 2025, https://www.vcbacked.co/company/arcus-biosciences. Accessed August 13, 2026.
VCBacked. (2025). Arcus Biosciences — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/arcus-biosciences
{{cite web |title=Arcus Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/arcus-biosciences |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated